Intelligence is not the bottleneck. “no matter how “intelligent” AI becomes, intelligence is often not the main bottleneck to things changing in the real world.” Ruxandra Bio argues that in medicine the grind of clinical trials, data access, and governance […]
The power of surrogate endpoints. “Surrogate endpoints: measurable intermediate biological signals that reliably predict clinical benefit, such as biomarkers or imaging readouts.” By utilizing these proxies, clinical trials can be significantly expedited, decreasing costs and increasing efficiency in drug development. […]
AI needs clinical trials. “Harvard Business School professor Karim Lakhani shares groundbreaking research on AI’s impact in the workplace through rigorous “clinical trials” at major organizations like BCG and Procter & Gamble. These studies reveal how AI fundamentally transforms work […]
I find it interesting for two reasons. 1) The World Health Organization is getting involved to set standards for studies and promote good design like control groups and randomization. 2) Traditional Chinese medicine is being tested, which I appreciate because […]
This is a real setback in FMT research. It highlights a need for better screening (like we do with blood). “The agency said two patients received donated stool that had not been screened for drug-resistant germs, leading it to halt […]